linjc16/ctgov huggingface dataset:
Establishment of Abbreviated Pancreatobiliary MRI Protocol

Study Overview
=================
Brief Summary
-----------------
This study aims to establish abbreviated PB MRI protocol for patients on regular imaging follow-up for pancreas cystic neoplasm.

Official Title
-----------------
Establishment of Abbreviated Pancreatobiliary MRI Using Compressed Sensing Technique for Pancreas Cystic Neoplasm Follow-up

Conditions
-----------------
Pancreas Cyst, Intraductal Papillary Mucinous Neoplasm

Intervention / Treatment
-----------------
* Diagnostic Test: Abbreviated PB MRI


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: on follow-up for pancreas intraductal mucinous neoplasm OR incidentally detected pancreas cyst (equal to or larger than 1cm) AND scheduled for CECT or has CECT within a months AND sign informed consent Exclusion Criteria: Any absolute or relative contra-indication for contrast-enhanced MRI No pancreas cystic neoplasm History of pancreatectomy History of any procedure for pancreatic cyst (ablation, aspiration...) in a year Hemosiderosis Suspicion of acute pancreatitis

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Follow-up participants<br>Patients who met eligibility criteria. Participants are going to undergo Abbreviated PB MRI. | Diagnostic Test: Abbreviated PB MRI<br>* Abbreviated PB MRI which targets table time of 10 minutes. For MRI acquisition, standard dose of commercially available MR contrast agent (Gadovist, Bayer, Germany) is used on weight-based dosing (0.1mmol/kg).<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Table time of Abbreviated PB MRI | total scan time | 1 day after PB MRI acquisition | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| In room time of Abbreviated PB MRI | time spent in room by participants (difference between walk-in and walk-out times) | 1 day after PB MRI acquisition | 
| Diagnostic confidence | subjective diagnostic confidence for pancreas cystic neoplasm on five point scale | 6 months after participants enrollment | 
| Image quality | overall image quality of Abbreviated PB MRI | 6 months after participants enrollment | 
| Requirement for re-examination | clinical need for re-examination due to suboptimal image quality | 6 months after participants enrollment | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
MRI
Telephone Call From Acute Care Physicians to Long Term Care Physicians: Impact on Transitional Care of Elderly Patients

Study Overview
=================
Brief Summary
-----------------
A telephone call from a physician taking care of a patient in the hospital to a physician in the long term care setting at the time of discharge can improve transitional care for elderly patients. We believe direct communication between physicians can reduce re-hospitalizations, medication errors, morbidity and mortality. No studies have been done that involve physician-to-physician sign-outs after hospital discharge to the nursing home. In our study, we would like to address the breakdown in the transfer of information to the nursing home setting.

Conditions
-----------------
Alzheimer Disease, Parkinson Disease, Dysphagia

Intervention / Treatment
-----------------
* Procedure: TELEPHONE CALL


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients transitioning from the Acute Care for The Elderly (ACE) Unit patients at Maimonides Medical Center to Metropolitan Jewish Geriatric Center (MJGC). Exclusion Criteria: AGE BELOW 65

Ages Eligible for Study
-----------------
Minimum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: TELEPHONE CALL|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
ALZHEIMER'S D-SE, PARKINSON'S D-SE, FRAILTY
Study Comparing Adapalene/BP Gel to EPIDUO® FORTE and Both to a Placebo Control in Treatment of Acne Vulgaris

Study Overview
=================
Brief Summary
-----------------
Bioequivalence with Clinical Endpoints.

Detailed Description
-----------------
Randomized, Double-Blind, Placebo-Controlled, Multiple-Site, Parallel Design, Bioequivalence with Clinical Endpoints.

Official Title
-----------------
A Multi-center, Double-blind, Randomized, Placebo, Controlled, Parallel-group Study, Comparing Adapalene/BP Gel, 0.3%/2.5% to EPIDUO® FORTE GEL and Both Active Treatments to a Placebo Control in the Treatment of Acne Vulgaris

Conditions
-----------------
Acne Vulgaris

Intervention / Treatment
-----------------
* Drug: Adapalene/BP gel, 0.3%/2.5%
* Drug: EPIDUO® FORTE
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy male or non pregnant female aged ≥ 12 and ≤ 40years with a clinical diagnosis of acne vulgaris. Exclusion Criteria: Female Subjects who are pregnant, nursing or planning to become pregnant during study participation

Ages Eligible for Study
-----------------
Minimum Age: 12 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Adapalene/BP gel, 0.3%/2.5%<br>Topical, once daily, for 84 days. | Drug: Adapalene/BP gel, 0.3%/2.5%<br>* Gel<br>* Other names: Adapalene, benzoyl peroxide;|
| Active Comparator: EPIDUO® FORTE<br>Topical, once daily, for 84 days. | Drug: EPIDUO® FORTE<br>* Gel<br>* Other names: Adapalene, benzoyl peroxide;|
| Placebo Comparator: Placebo<br>Topical, once daily, for 84 days. | Drug: Placebo<br>* Gel<br>* Other names: Vehicle;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in inflammatory lesion counts | Percent change from baseline to week 12 in the inflammatory (papules and pustules) lesion counts | Week 12 | 
| Change in non-inflammatory lesion counts | Percent change from baseline to week 12 in the non-inflammatory (open and closed comedones) lesion counts | Week 12 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical response of success | The proportion of subjects with a clinical response of success at week 12, success defined as an Investigator's Global Assessment score that is at least two grades less than the baseline assessment | Week 12 |
Evaluation of the Satisfaction of the Patients Operated for a Mild Hyperplasie of the Prostate by Laser in Ambulatory Surgery

Study Overview
=================
Brief Summary
-----------------
Every year more than 70 000 interventions for prostatic adenoma are realized. Several type of surgery are realized going of the ambulatory to longer hospital lengths of stay. There are also several techniques.However it appears that ambulatory surgery is less costly. The arguments of surgeons are patients reluctance or the difficulty to manage in case of complication. The aim of the study is to show that there is a good acceptance from patient with a good level of satisfaction at day 30.

Official Title
-----------------
Evaluation of the Satisfaction of the Patients Operated for a Mild Hyperplasie of the Prostate by Laser in Ambulatory Surgery

Conditions
-----------------
Prostatic Hyperplasia

Intervention / Treatment
-----------------
* Procedure: laser surgery


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age> 18 patient with benign prostatic hyperplasia ambulatory eligibility Exclusion Criteria: recused for ambulatory surgery Patients operated by surgeons not having ended their learning curve.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: laser surgery|laser surgery|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| patient satisfaction | analogic scale (0 to 10) | Day 30 |
Supplement Intake in Infertile Men;the Effect on Sperm Parameters,Fertilization Rate and Embryo Quality

Study Overview
=================
Brief Summary
-----------------
The vitamin,minerals and amino acid supplementation for 3 months will improve the semen parameters,fertilization rate and embryo quality in subfertile men undergoing IVF treatment

Detailed Description
-----------------
With the supplement intake containing amino acids, vitamins and minerals designed to improve sperm parameters, the couples undergoing IVF treatment will benefit as the change and improvement of sperm parameters will increase the fertilization rate and improve the embryo quality thus allowing shorter time for pregnancy achievement and less frustration with long duration of treatments

Official Title
-----------------
Vitamins ,Minerals and Amino Acids Supplement Intake in Infertile Men;the Effect on Sperm Parameters,Fertilization Rate and Embryo Quality. A Double Blind Randomized Controlled Trial

Conditions
-----------------
Oligospermia

Intervention / Treatment
-----------------
* Dietary Supplement: Vitamale


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: healthy male age 20-50 at least one IVF cycle without pregnancy sperm parameters: Oligospermia 5-20*106 Teratospermia 6-14% normal forms Asthenospermia <30% motility Exclusion Criteria: female factor infertility age > 50 or under 20 testicular problem on physical examination history of malignancy and /or chemotherapy usage of antiandrogen/testosterone history of drug abuse/alcohol a known endocrinological problem current STD or genitourinary infection Retrograde Ejaculation Y chromosome microdeletion Karyotype abnormalities

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: vitamale<br> | Dietary Supplement: Vitamale<br>* men will receive the vitamale dietary supplement compared to a sham pill<br>* Other names: amino acid minerals and vitamin supplement;|
| Placebo Comparator: sham pill<br> | Dietary Supplement: Vitamale<br>* men will receive the vitamale dietary supplement compared to a sham pill<br>* Other names: amino acid minerals and vitamin supplement;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Sperm parameters | Men suffering from a male factor problem and after one failed IVF treatment will be given the supplement for 3 months after which the sperm parametrs will be evaluated and compared to pre-supplement data and later the embryo quality and fertilization rate will reviewed analyzed and compared | 3 months of treatment |
Characterization of Pulmonary Artery Stenoses in Alagille Syndrome - a Medical Record Review

Study Overview
=================
Brief Summary
-----------------
Patients who have Alagille Syndrome (AGS) also frequently have blockages (or stenoses) of their pulmonary arteries. Little is known about the degree or variability of these stenoses, or the effect of this disease on the right ventricle (the chamber of the heart which pumps blood to the lungs). This study will first quantify and describe pulmonary artery stenosis in patients with Alagille Syndrome. The study will also assess the effect of these stenoses on the right ventricle. The investigators hope to learn the degree and characteristics of pulmonary artery stenosis in Alagille Syndrome. The investigators also hope to learn the effect of this pulmonary artery stenosis on the right ventricle in patients with Alagille Syndrome. This information is critical in the management of patients with Alagille syndrome, as there is currently no data to guide clinicians on the management of pulmonary artery stenosis. Furthermore, the information from this study may help physicians manage pulmonary artery stenosis in other patients as well.

Detailed Description
-----------------
The investigators hope to learn the degree and characteristics of pulmonary artery stenosis in Alagille Syndrome. We also hope to learn the effect of this pulmonary artery stenosis on the right ventricle in patients with Alagille Syndrome. This information is critical in the management of patients with Alagille syndrome, as there is currently no data to guide clinicians on the management of pulmonary artery stenosis. Furthermore, the information from this study may help physicians manage pulmonary artery stenosis in other patients as well. For the third aim, we hope to learn about the different blood vessel abnormalities in the brain, and which abnormalities are most likely to lead to stroke.

Official Title
-----------------
Characterization of Pulmonary Artery Stenoses in Alagille Syndrome - a Medical Record

Conditions
-----------------
Alagille Syndrome

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of Alagille Syndrome Exclusion Criteria: None
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Study<br>Patients with alagille syndrome | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assessment of PA in Alagille Patient |  | Open |
Quantifying Nitrous Oxide Effect on Depth of Anaesthesia Using Theoretically Based Time Series Modelling

Study Overview
=================
Brief Summary
-----------------
Our hypothesis is that a new method of depth of anaesthesia monitoring, using theoretically based time series modelling will result in improved ability to determine nitrous oxide anaesthetic effect

Detailed Description
-----------------
We randomised patients to 0% 33% or 66% nitrous oxide during sevoflurane induction and measured anesthetic endpoints.

Official Title
-----------------
Quantifying Nitrous Oxide Effect on Depth of Anaesthesia Using Theoretically Based Time Series Modelling

Conditions
-----------------
Depth of Anaesthesia

Intervention / Treatment
-----------------
* Drug: Nitrous oxide


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Aged 18 years or older Presenting for surgery under general anaesthesia Exclusion Criteria: Poor English language comprehension Risk of reflux Epilepsy or other EEG abnormality

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: 1<br>0% nitrous oxide | Drug: Nitrous oxide<br>* nitrous oxide by inhalation during induction<br>* Other names: No other names were used;|
| Active Comparator: 2<br>33% nitrous oxide | Drug: Nitrous oxide<br>* nitrous oxide by inhalation during induction<br>* Other names: No other names were used;|
| Active Comparator: 3<br>66% nitrous oxide | Drug: Nitrous oxide<br>* nitrous oxide by inhalation during induction<br>* Other names: No other names were used;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| EEG index value during three concentrations of nitrous oxide |  | During induction of anaesthesia |
Diagnostic Accuracy of the Preoperative Clinical Examination in Upper Limb Injuries

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the accuracy of preoperative clinical examination in penetrating injuries

Detailed Description
-----------------
Penetrating injuries is a common cause of severe neurovascular damage, both in adults and children.we evaluated the accuracy of the preoperative clinical examination in depicting lesions caused by penetrating wounds of hands or forearms.

Official Title
-----------------
Study of Accuracy of Preoperative Examination in Penetrating Wound

Conditions
-----------------
Penetrating Injury in Upper Limb

Intervention / Treatment
-----------------
* Other: exploration


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Deep penetrating injury to upper limb Exclusion Criteria: none
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: determining damaged tissue<br> | Other: exploration<br>* exploration of wound for determining damaged tissue<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| number of determined tendon | we evalauted tendon injuries without exploration of wound | 5 min after admission | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| number of determined injured nerves | we evaluated the number of detemined injured nerves without exploration of wound | 5 min after admision | 
| number of damaged arteries | we evaluated the number of detemined injured arteries without exploration of wound | 5 min after admission | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Clinical Examination, Accuracy, Hand, Tendon, Injury.
Retrospective Analysis of Veritas in Breast Reconstruction

Study Overview
=================
Brief Summary
-----------------
Retrospective data collection of the use of Veritas in breast reconstruction surgery

Detailed Description
-----------------
This is a multi-center study to retrospectively collect data on the use of Veritas Collagen Matrix in breast reconstruction. Data will be collected on post-operative complications in immediate breast reconstruction and then be compared to literature reported post-operative complication rates associated with the use of acellular dermal matrix in immediate breast reconstruction.

Official Title
-----------------
Retrospective Analysis of Veritas in Breast Reconstruction (RAVE)

Conditions
-----------------
Seroma, Necrosis, Infection

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 18 years or older Patients who underwent mastectomy with immediate breast reconstruction using Veritas collagen matrix Patients who underwent mastectomy with single stage procedures or two-stage procedures using Veritas collagen matrix Exclusion Criteria: Patients who underwent delayed breast reconstruction Reconstruction with something other than Veritas collagen matrix Breasts that were created with DIEP or TRAM procedures

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Veritas<br>Breast reconstruction with Veritas | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Clinical Study of the CardioFocus Endoscopic Ablation System for the Treatment of Symptomatic AF

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the safety and effectiveness of the endoscopic ablation system - adaptive contact (EAS-AC) in treated paroxysmal atrial fibrillation (PAF) with pulmonary vein isolation (PVI).

Official Title
-----------------
Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (CFEAS- AC) for the Treatment of Symptomatic Atrial Fibrillation

Conditions
-----------------
Paroxysmal Atrial Fibrillation

Intervention / Treatment
-----------------
* Device: CardioFocus EAS-AC


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Symptomatic, Paroxysmal atrial fibrillation (AF) 18 to 70 years of age Failure of at least one AAD Others Exclusion Criteria: Generally good overall health as determined by multiple criteria Willing to participate in a study Others

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: EAS-AC<br>PVI with EAS-AC | Device: CardioFocus EAS-AC<br>* PVI for PAF<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Chronic Effectiveness in Treating PAF as Demonstrated by no AF Recurrences After the Blanking Period and During the 12-month Follow-up Period. |  | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Treatment of PAF using EAS-AC